Latest Insider Transactions at Soleno Therapeutics Inc (SLNO)
This section provides a real-time view of insider transactions for Soleno Therapeutics Inc (SLNO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of SOLENO THERAPEUTICS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of SOLENO THERAPEUTICS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 01
2025
|
Patricia C Hirano |
SELL
Open market or private sale
|
Direct |
3,782
-12.27%
|
$264,740
$70.11 P/Share
|
|
Mar 28
2025
|
Matthew Pauls |
SELL
Open market or private sale
|
Direct |
5,937
-47.74%
|
$421,527
$71.55 P/Share
|
|
Mar 28
2025
|
Matthew Pauls |
BUY
Exercise of conversion of derivative security
|
Direct |
5,937
+32.31%
|
$23,748
$4.6 P/Share
|
|
Mar 28
2025
|
Patricia C Hirano |
SELL
Open market or private sale
|
Direct |
27,662
-14.46%
|
$1,908,678
$69.87 P/Share
|
|
Mar 28
2025
|
Patricia C Hirano |
BUY
Exercise of conversion of derivative security
|
Direct |
2,691
+4.4%
|
$88,803
$33.6 P/Share
|
|
Mar 28
2025
|
Vivo Opportunity, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
333,557
-6.96%
|
$23,348,990
$70.6 P/Share
|
|
Mar 27
2025
|
James H Mackaness CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
90,622
-5.78%
|
$6,252,918
$69.46 P/Share
|
|
Mar 27
2025
|
James H Mackaness CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
70,000
+8.63%
|
$630,000
$9.22 P/Share
|
|
Mar 27
2025
|
Meredith Manning Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
45,249
-6.82%
|
$3,122,181
$69.03 P/Share
|
|
Mar 27
2025
|
Meredith Manning Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,000
+31.0%
|
$1,702,000
$46.31 P/Share
|
|
Mar 27
2025
|
Kristen Yen |
SELL
Open market or private sale
|
Direct |
95,500
-12.43%
|
$6,494,000
$68.71 P/Share
|
|
Mar 27
2025
|
Kristen Yen |
BUY
Exercise of conversion of derivative security
|
Direct |
40,638
+11.97%
|
$162,552
$4.25 P/Share
|
|
Mar 27
2025
|
Michael F. Huang Sr. VP of Clinical Development |
SELL
Open market or private sale
|
Direct |
14,583
-3.66%
|
$1,006,227
$69.36 P/Share
|
|
Mar 27
2025
|
Michael F. Huang Sr. VP of Clinical Development |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+17.6%
|
$210,000
$21.93 P/Share
|
|
Mar 27
2025
|
Bhatnagar Anish CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
699,095
-6.94%
|
$47,538,460
$68.58 P/Share
|
|
Mar 27
2025
|
Bhatnagar Anish CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
523,809
+8.49%
|
$7,857,135
$15.9 P/Share
|
|
Mar 27
2025
|
Patricia C Hirano |
SELL
Open market or private sale
|
Direct |
128,653
-9.36%
|
$8,877,057
$69.23 P/Share
|
|
Mar 27
2025
|
Patricia C Hirano |
BUY
Exercise of conversion of derivative security
|
Direct |
72,140
+7.83%
|
$721,400
$10.74 P/Share
|
|
Mar 27
2025
|
Vivo Opportunity, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,100,000
-18.67%
|
$73,700,000
$67.8 P/Share
|
|
Mar 26
2025
|
Vivo Opportunity, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
400,000
-6.36%
|
$26,000,000
$65.8 P/Share
|
|
Jan 21
2025
|
Patricia C Hirano |
BUY
Grant, award, or other acquisition
|
Direct |
6,400
+5.39%
|
-
|
|
Jan 21
2025
|
Michael F. Huang Sr. VP of Clinical Development |
BUY
Grant, award, or other acquisition
|
Direct |
6,400
+13.39%
|
-
|
|
Jan 21
2025
|
James H Mackaness CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
14,500
+10.34%
|
-
|
|
Jan 21
2025
|
Meredith Manning Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,600
+20.24%
|
-
|
|
Jan 21
2025
|
Kristen Yen |
BUY
Grant, award, or other acquisition
|
Direct |
6,400
+7.16%
|
-
|
|
Jan 21
2025
|
Bhatnagar Anish CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
53,900
+6.69%
|
-
|
|
Jan 03
2025
|
Bhatnagar Anish CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
10,154
-1.43%
|
$467,084
$46.18 P/Share
|
|
Jan 03
2025
|
Patricia C Hirano |
SELL
Open market or private sale
|
Direct |
1,459
-1.36%
|
$67,114
$46.18 P/Share
|
|
Jan 03
2025
|
James H Mackaness CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,791
-3.29%
|
$174,386
$46.18 P/Share
|
|
Jan 03
2025
|
Kristen Yen |
SELL
Open market or private sale
|
Direct |
2,340
-2.96%
|
$107,640
$46.18 P/Share
|
|
Jan 02
2025
|
Bhatnagar Anish CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
10,937
-0.76%
|
$492,165
$45.64 P/Share
|
|
Jan 02
2025
|
Patricia C Hirano |
SELL
Open market or private sale
|
Direct |
1,571
-0.72%
|
$70,695
$45.64 P/Share
|
|
Jan 02
2025
|
James H Mackaness CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,083
-1.72%
|
$183,735
$45.64 P/Share
|
|
Jan 02
2025
|
Kristen Yen |
SELL
Open market or private sale
|
Direct |
2,520
-1.55%
|
$113,400
$45.64 P/Share
|
|
Oct 01
2024
|
James H Mackaness CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
8,077
-3.19%
|
$395,773
$49.8 P/Share
|
|
Oct 01
2024
|
Kristen Yen |
SELL
Open market or private sale
|
Direct |
3,108
-1.84%
|
$152,292
$49.8 P/Share
|
|
Oct 01
2024
|
Patricia C Hirano |
SELL
Open market or private sale
|
Direct |
3,108
-1.39%
|
$152,292
$49.8 P/Share
|
|
Oct 01
2024
|
Bhatnagar Anish CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
21,633
-1.46%
|
$1,060,017
$49.8 P/Share
|
|
Aug 29
2024
|
James H Mackaness CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
6,870
-2.58%
|
$322,890
$47.5 P/Share
|
|
Aug 29
2024
|
Kristen Yen |
SELL
Open market or private sale
|
Direct |
5,435
-3.05%
|
$255,445
$47.5 P/Share
|
|
Aug 29
2024
|
Bhatnagar Anish CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
58,391
-3.69%
|
$2,744,377
$47.5 P/Share
|
|
Aug 29
2024
|
Patricia C Hirano |
SELL
Open market or private sale
|
Direct |
5,435
-2.33%
|
$255,445
$47.5 P/Share
|
|
Aug 29
2024
|
Vivo Opportunity, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
100,000
-1.56%
|
$4,700,000
$47.22 P/Share
|
|
Aug 28
2024
|
James H Mackaness CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
6,661
-2.39%
|
$313,067
$47.61 P/Share
|
|
Aug 28
2024
|
Kristen Yen |
SELL
Open market or private sale
|
Direct |
5,270
-2.8%
|
$247,690
$47.61 P/Share
|
|
Aug 28
2024
|
Bhatnagar Anish CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
56,613
-3.36%
|
$2,660,811
$47.61 P/Share
|
|
Aug 28
2024
|
Patricia C Hirano |
SELL
Open market or private sale
|
Direct |
5,270
-2.17%
|
$247,690
$47.61 P/Share
|
|
Aug 28
2024
|
Vivo Opportunity, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
425,000
-6.23%
|
$19,975,000
$47.35 P/Share
|
|
Aug 27
2024
|
Vivo Opportunity, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
500,000
-6.83%
|
$24,000,000
$48.73 P/Share
|
|
Aug 15
2024
|
Dawn Carter Bir |
BUY
Grant, award, or other acquisition
|
Direct |
13,000
+50.0%
|
-
|